Glucagon receptor antagonists for the treatment of type II diabetes: current prospects [0.03%]
胰高血糖素受体拮抗剂治疗2型糖尿病的现状展望
Stevan W Djuric,Nelson Grihalde,Chun Wel Lin
Stevan W Djuric
As the incidence of Type II diabetes (T2DM) will increase to 200 million cases worldwide by 2010, the search for new, effective agentsfor its treatment has been pushed into overdrive. According to Unger's bihormonal hypothesis, elevated lev...
Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes [0.03%]
蛋白酪氨酸磷酸酶-1B在糖耐量异常和2型糖尿病治疗中的作用及其机制研究
Gang Liu,James M Trevillyan
Gang Liu
Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of the insulin signal transduction cascade, initiated when insulin binds to the insulin receptor. PTP1B-deficient mice are more sensitive to insulin, and have improved glycemic...
Claudia S Leopold,Howard I Maibach
Claudia S Leopold
Corixa, Genesis and Medicis are developing PVAC, an immunomodulator derived from killed Mycobacterium vaccae and licensed from SR Pharma [309860], [312958], for the potential treatment of psoriasis [365490]. In February 2001, phase II trial...
Margitta Worm
Margitta Worm
Atopic dermatitis (AD) has been treated with topical glucocorticosteroids for decades. With the introduction of the topical immune modulators tacrolimus and pimecrolimus, a new treatment era has begun. The knowledge on pathophysiological in...
Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases [0.03%]
抗肿瘤坏死因子α治疗炎症性皮肤病的潜力
Giampiero Girolomoni,Saveria Pastore,Cristina Albanesi et al.
Giampiero Girolomoni et al.
Tumor necrosis factor-a (TNFalpha) plays an important role in the initiation and persistence of inflammation in a variety of skin disorders. The availability of selective TNFalpha blockers has provided new therapeutic opportunities. TNFa in...
Dale Barnard
Dale Barnard
Viramidine, an analog of ribavirin is a broad-spectrum antiviral under development by Ribapharm (previously the R&D division of ICN Pharmaceuticals) for the potential treatment of viral infections [378507]. In September 2000, phase I trials...
Jignesh Patel,Ashim K Mitra
Jignesh Patel
Achillion, under license from Vion, is developing the nucleoside analog ACH-126443 (beta-L-Fd4C), a reverse transcriptase (RT) inhibitor, for the potential treatment of HIV and hepatitis B virus (HBV) infection. The compound is one of a ser...
The role of viruses in human cancer development and antiviral approaches for intervention [0.03%]
病毒诱发人类肿瘤及其抗病毒防治策略研究进展
John F Kadow,Alicia Regueiro-Ren,Steven P Weinheimer
John F Kadow
Viruses are estimated to be linked to at least 15% of human cancers. Hepatitis B and C viruses, human papilloma viruses, Epstein-Barr virus, human herpes virus-8 and human T-cell leukemia virus have been definitively linked to human cancer....
Strategies for the identification of inhibitors of West Nile virus and other flaviviruses [0.03%]
鉴定西尼罗病毒和其他黄病毒感染的抑制剂策略
Pei-Yong Shi
Pei-Yong Shi
The recent outbreaks of West Nile virus (WNV) and other emerging and re-emerging flaviviruses, have made prevention and treatment of flavivirus infections a global public health priority. No inhibitor is currently available for use as an an...
Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients [0.03%]
cidofovir治疗免疫抑制患者抗DNA病毒(除CMV以外)感染的作用
Robert Snoeck,Eric De Clercq
Robert Snoeck
Cidofovir is a nucleotide analog marketed for the treatment of human cytomegalovirus infections in immunocompromised patients. An increasing number of reports have appeared on the use of cidofovir for the treatment of other severe DNA virus...